Dr. Anthony P. Adamis Joins Eyetech Pharmaceuticals to Lead Research Team Eyetech Pharmaceuticals,Tuesday, June 25, 2002 New York, NY. June 25, 2002 - Eyetech Pharmaceuticals, Inc., a privately-held biotechnology company dedicated to the development and commercialization of novel drugs for the treatment of eye disease, today announced that Harvard Medical School Associate Professor, Dr. Anthony P. Adamis, will join Eyetech as Senior Vice President of Research and Chief Scientific Officer, effective July 1, 2002. Dr. Adamis, 43, has been affiliated with Eyetech since its inception in April 2000, as a member of its Scientific Advisory Board and as Director of Pre-clinical Research. Eyetech co-founder and CEO, Dr. David Guyer, stated that Dr. Adamis will be responsible for the discovery and development of new proprietary compounds that the company expects will contribute to an extensive pre-clinical product pipeline for future investigation. Dr. Adamis will be responsible for overseeing a team of 20 researchers in laboratories located in the Boston area. "The addition of Dr. Adamis to our management and research teams further validates the promising research and development being conducted at Eyetech to address unmet medical needs in the area of ocular vascular disease," said Dr. Guyer. "Dr. Adamis' wealth of knowledge and experience will provide invaluable synergies to our mission of reducing and preventing vision loss related to eye disease. We look forward to Dr. Adamis' immediate contribution to the enhancement of our product pipeline and the identification of promising compounds to take into our clinical trial programs." Prior to joining Eyetech, Dr. Adamis was an Associate Professor of Ophthalmology at the Harvard Medical School and served as a Principal Investigator and Co-Director of the Retina Research Institute for Diabetic Retinopathy and Macular Degeneration at Massachusetts Eye and Ear Infirmary, a teaching affiliate of Harvard Medical School. Dr. Adamis' affiliation with these institutions dates back to 1989, when he began his clinical and research fellowships at the Massachusetts Eye and Ear Infirmary. Dr. Adamis also completed a vascular biology fellowship with Dr. Judah Folkman at the Children's Hospital of Boston and later served as a Principal Investigator in the Surgical Research Laboratory at Children's Hospital. A leading expert on ocular vascular disease and ocular drug delivery, Dr. Adamis is best known for his co-discovery of the role that vascular endothelial growth factor (VEGF) plays in neovascularization and vascular permeability related to various diseases of the eye. His findings sparked important research advances in the treatment of such conditions as macular degeneration and diabetic retinopathy and continue to shape the course of research in these areas today. "I am excited at the prospect of working at Eyetech Pharmaceuticals which is at the forefront of discovering and developing sight-saving therapeutics," said Dr. Adamis. "Eyetech possesses a pipeline with extraordinary potential and I am eager to play a vital role in shaping that potential into needed therapeutic treatments." Eyetech Pharmaceuticals, Inc., is a privately-held, New York City-based biopharmaceutical company dedicated to development and commercialization of novel drugs to reduce and prevent vision loss caused by eye disease. Eyetech is also focused on developing new technologies to deliver drugs safely to the back of the eye. The company has brought together experienced pharmaceutical industry executives and a world-class team of thought-leaders in ophthalmology from leading medical centers and medical schools, such as Harvard Medical School, Stanford, the University of Chicago, Johns Hopkins and Columbia, to build a pipeline of drug candidates to address significant unmet medical needs related to various diseases of the eye.